First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer

Among first-line regimens for unresectable locally advanced or metastatic biliary tract cancers, how do progression-free survival, overall survival, and objective response rate associated with different therapies compare?Among 33 randomized clinical trials involving 7303 patients, gemcitabine and cisplatin (GC) plus durvalumab, GC plus S-1, gemcitabine and oxaliplatin (GO) plus panitumumab, and GO plus cetuximab demonstrated the greatest consistency in the surface under the cumulative ranking curve value for progression-free survival, overall survival, and objective response rate, making these the top 5 regimens in terms of overall outcomes. These regimens also demonstrated a comparable risk of hematological toxic effects.These findings suggest these 5 regimens were associated with the best overall treatment outcome as well as hematological safety in patients with locally advanced or metastatic biliary tract cancers.

Corresponding Author: Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, Department of Surgery, Ohio State University, Wexner Medical Center, 395 W 12th Ave, Ste 670, Columbus, OH 43210 (tim.pawlik@osumc.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.